Your session is about to expire
← Back to Search
S-nitrosylation Therapy
GSNO for Bronchopulmonary Dysplasia
Phase 1
Waitlist Available
Led By Thomas Raffay, MD
Research Sponsored by University Hospitals Cleveland Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights
Study Summary
This study is evaluating whether a new treatment for bronchopulmonary dysplasia may be effective.
Eligible Conditions
- Bronchopulmonary Dysplasia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Treatment Emergent Adverse Events
Secondary outcome measures
Change in GSNO catabolism pre/post treatment
Change in oxygen saturation index
Intermittent hypoxemia as measured by oxygen saturation post treatment
+2 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: GSNO therapyExperimental Treatment1 Intervention
Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
Find a Location
Who is running the clinical trial?
University Hospitals Cleveland Medical CenterLead Sponsor
317 Previous Clinical Trials
340,237 Total Patients Enrolled
Thomas Raffay, MDPrincipal InvestigatorUniversity Hospitals Cleveland Medical Center
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger